<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Acetylsalicylic acid</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00945</strong>&#160; (APRD00264, EXPT00475)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00945/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00945/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00945.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00945.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00945.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00945.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00945.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00945">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>2-Acetoxybenzenecarboxylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2-Acetoxybenzoic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Acetylsalicylate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Acide ac&#233;tylsalicylique</td><td>French</td><td>INN</td></tr><tr><td>&#225;cido acetilsalic&#237;lico</td><td>Spanish</td><td>INN</td></tr><tr><td>Acidum acetylsalicylicum</td><td>Latin</td><td>INN</td></tr><tr><td>ASA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Aspirin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN</td></tr><tr><td>Azetylsalizyls&#228;ure</td><td>German</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>o-acetoxybenzoic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>O-acetylsalicylic acid</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>o-carboxyphenyl acetate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Polopiryna</td><td>Polish</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Acenterine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Acetophen</td><td>Merck</td></tr><tr><td>Adiro</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Aspergum</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Aspirin</td><td>Bayer HealthCare LLC.</td></tr><tr><td>Aspro</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Bayer Aspirin</td><td>Bayer HealthCare LLC.</td></tr><tr><td>Easprin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ecotrin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Empirin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Entrophen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nu-seals</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rhodine</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Rhonal</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Solprin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Solprin acid</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>St. Joseph Aspirin for Adults</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tasprin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Aspirin with Stomach Guard</td><td>Acetylsalicylic Acid + Calcium Carbonate + Magnesium Carbonate + Magnesium Oxide</td></tr><tr><td>Extra Strength Aspirin Backache</td><td>Acetylsalicylic Acid + Methocarbamol</td></tr><tr><td>Synalgos</td><td>Caffeine + Acetylsalicylic acid + Dihydrocodeine</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/fibrinolytic-agents">Fibrinolytic Agents</a></li>
<li><a href="/mesh/platelet-aggregation-inhibitors">Platelet Aggregation Inhibitors</a></li>
<li><a href="/mesh/anti-inflammatory-agents-non-steroidal">Anti-Inflammatory Agents, Non-Steroidal</a></li>
<li><a href="/mesh/cyclooxygenase-inhibitors">Cyclooxygenase Inhibitors</a></li>
<li><a href="/mesh/antipyretics">Antipyretics</a></li>
<li><a href="/mesh/salicylates">Salicylates</a></li></ul></td></tr><tr><th>CAS number</th><td>50-78-2</td></tr><tr><th>Weight</th><td>Average: 180.1574<br>Monoisotopic: 180.042258744</td></tr><tr><th>Chemical Formula</th><td>C<sub>9</sub>H<sub>8</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>BSYNRYMUTXBXSQ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(acetyloxy)benzoic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(=O)OC1=CC=CC=C1C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00945.gif?1265922773">show</a>(8.27 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenol Esters</td></tr><tr><th>Direct parent</th><td>Phenol Esters</td></tr><tr><th>Alternative parents</th><td>Salicylic Acids; Benzoic Acids; Phenol Ethers; Benzoyl Derivatives; Alkyl Aryl Ethers; Dicarboxylic Acids and Derivatives; Carboxylic Acid Esters; Enolates; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>benzoyl; phenol ether; alkyl aryl ether; dicarboxylic acid derivative; carboxylic acid ester; ether; carboxylic acid; carboxylic acid derivative; polyamine; enolate</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenol esters. These are aromatic compounds containing a benzene ring substituted by an hydroxyl group and an ester group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For use in the temporary relief of various forms of pain, inflammation associated with various conditions (including rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, and ankylosing spondylitis), and is also used to reduce the risk of death and/or nonfatal myocardial infarction in patients with a previous infarction or unstable angina pectoris.</td></tr><tr><th>Pharmacodynamics</th><td>Acetylsalicylic acid is an analgesic, antipyretic, antirheumatic, and anti-inflammatory agent. Acetylsalicylic acid's mode of action as an antiinflammatory and antirheumatic agent may be due to inhibition of synthesis and release of prostaglandins. Acetylsalicylic acid appears to produce analgesia by virtue of both a peripheral and CNS effect. Peripherally, acetylsalicylic acid acts by inhibiting the synthesis and release of prostaglandins. Acting centrally, it would appear to produce analgesia at a hypothalamic site in the brain, although the mode of action is not known. Acetylsalicylic acid also acts on the hypothalamus to produce antipyresis; heat dissipation is increased as a result of vasodilation and increased peripheral blood flow. Acetylsalicylic acid's antipyretic activity may also be related to inhibition of synthesis and release of prostaglandins.</td></tr><tr><th>Mechanism of action</th><td>The analgesic, antipyretic, and anti-inflammatory effects of acetylsalicylic acid are due to actions by both the acetyl and the salicylate portions of the intact molecule as well as by the active salicylate metabolite. Acetylsalicylic acid directly and irreversibly inhibits the activity of both types of cyclooxygenase (COX-1 and COX-2) to decrease the formation of precursors of prostaglandins and thromboxanes from arachidonic acid. This makes acetylsalicylic acid different from other NSAIDS (such as diclofenac and ibuprofen) which are reversible inhibitors. Salicylate may competitively inhibit prostaglandin formation. Acetylsalicylic acid's antirheumatic (nonsteroidal anti-inflammatory) actions are a result of its analgesic and anti-inflammatory mechanisms; the therapeutic effects are not due to pituitary-adrenal stimulation. The platelet aggregation-inhibiting effect of acetylsalicylic acid specifically involves the compound's ability to act as an acetyl donor to cyclooxygenase; the nonacetylated salicylates have no clinically significant effect on platelet aggregation. Irreversible acetylation renders cyclooxygenase inactive, thereby preventing the formation of the aggregating agent thromboxane A2 in platelets. Since platelets lack the ability to synthesize new proteins, the effects persist for the life of the exposed platelets (7-10 days). Acetylsalicylic acid may also inhibit production of the platelet aggregation inhibitor, prostacyclin (prostaglandin I2), by blood vessel endothelial cells; however, inhibition prostacyclin production is not permanent as endothelial cells can produce more cyclooxygenase to replace the non-functional enzyme.</td></tr><tr><th>Absorption</th><td>Absorption is generally rapid and complete following oral administration but may vary according to specific salicylate used, dosage form, and other factors such as tablet dissolution rate and gastric or intraluminal pH.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>High (99.5%) to albumin. Decreases as plasma salicylate concentration increases, with reduced plasma albumin concentration or renal dysfunction, and during pregnancy.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Acetylsalicylic acid is rapidly hydrolyzed primarily in the liver to salicylic acid, which is conjugated with glycine (forming salicyluric acid) and glucuronic acid and excreted largely in the urine.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Acetylsalicylic acid</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00578">1-Salicylate glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/596">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>The plasma half-life is approximately 15 minutes; that for salicylate lengthens as the dose increases: doses of 300 to 650 mg have a half-life of 3.1 to 3.2 hours; with doses of 1 gram, the half-life is increased to 5 hours and with 2 grams it is increased to about 9 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 250 mg/kg; Oral, rabbit: LD<sub>50</sub> = 1010 mg/kg; Oral, rat: LD<sub>50</sub> = 200 mg/kg. Effects of overdose include: tinnitus, abdominal pain, hypokalemia, hypoglycemia, pyrexia, hyperventilation, dysrhythmia, hypotension, hallucination, renal failure, confusion, seizure, coma, and death.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Acetylsalicylic Acid Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00083?highlight%5Bcompounds%5D%5B%5D=DB00945&amp;highlight%5Bproteins%5D%5B%5D=DB00945">SMP00083</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cytochrome P450 2C9<br>Gene symbol: CYP2C9<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P11712" target="_blank">P11712 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs1057910" target="_blank">rs1057910 <span class="glyphicon glyphicon-new-window"> </span></a></td><td>CYP2C9*1</td><td>C Allele</td><td>Poor drug metabolizer, lower dose requirements</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/12893985" target="_blank" title="Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J: Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics. 2003 Aug;13(8):473-80.">12893985 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Integrin beta-3<br>Gene symbol: ITGB3<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P05106" target="_blank">P05106 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs5918" target="_blank">rs5918 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>T &gt; C</td><td>Patients are more resistant to the anti-thrombotic effects of aspirin</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/11723016" target="_blank" title='# Undas A, Brummel K, Musial J, Mann KG, Szczeklik A: Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation. 2001 Nov 27;104(22):2666-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11723016'>11723016 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Adverse Reaction</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Leukotriene C4 synthase<br>Gene symbol: LTC4S<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/Q16873" target="_blank">Q16873 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs730012" target="_blank">rs730012 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>C allele</td><td>Aspirin-induced urticaria</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/16433794" target="_blank" title="Mastalerz L, Setkowicz M, Sanak M, Rybarczyk H, Szczeklik A: Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. Br J Dermatol. 2006 Feb;154(2):256-60.">16433794 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9645</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9376</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6607</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.685</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9118</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9615</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.914</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7518</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7225</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9046</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9576</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9445</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9611</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9557</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9326
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8356
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.9067
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6386 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9433
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9799
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Bayer healthcare llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://BASF%20Corp.">BASF Corp.</a></li>
<li><a href="http://www.excellium.com">Excellium Pharmaceutical Inc.</a></li>
<li>Harvest Pharmaceuticals Inc.</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.rtherapeutics.com">Rosedale Therapeutics</a></li>
<li><a href="http://timecaplabs.com">Time-Cap Labs</a></li>
<li><a href="http://www.urlpharma.com">United Research Laboratories Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Gum</td><td>Oral</td><td></td></tr><tr><td>Liquid</td><td>Oral</td><td></td></tr><tr><td>Powder</td><td>Oral</td><td></td></tr><tr><td>Solution / drops</td><td>Oral</td><td></td></tr><tr><td>Suppository</td><td>Rectal</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr><tr><td>Tablet, chewable</td><td>Oral</td><td></td></tr><tr><td>Tablet, coated</td><td>Oral</td><td></td></tr><tr><td>Tablet, delayed release</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Entrophen 10 650 mg Enteric-Coated Tablet</td><td>0.09USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>135 &#176;C</td><td>PhysProp</td></tr><tr><td>boiling point</td><td>140 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>4600 mg/L (at 25 &#176;C)</td><td>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</td></tr><tr><td>logP</td><td>1.19</td><td>HANSCH,C ET AL. (1995)</td></tr><tr><td>Caco2 permeability</td><td>-5.06</td><td>ADME Research, USCD</td></tr><tr><td>pKa</td><td>3.49 (at 25 &#176;C)</td><td>MERCK INDEX (1983)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.46e+00 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.43</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.24</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2.1</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>3.41</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-7.1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>-1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>63.6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>44.45</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>17.1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/c_ms/215">Gas-MS Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_one_d/1776">1H NMR Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1777">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1778">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/1779">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5543">MS/MS Spectrum EI-B (Unknown) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5544">MS/MS Spectrum CI-B (Unknown) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/5545">MS/MS Spectrum GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies	) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/6617">MS/MS Spectrum GC-MS </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1716">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Marino Gobetti, Guido Vandoni, &#8220;Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them.&#8221; U.S. Patent US4563443, issued March, 1981.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=4563443&amp;tbm=pts" target="_blank">US4563443 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Macdonald S: Aspirin use to be banned in under 16 year olds. <span class="caps">BMJ</span>. 2002 Nov 2;325(7371):988. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12411346">Pubmed</a></li>
	<li>Sneader W: The discovery of aspirin: a reappraisal. <span class="caps">BMJ</span>. 2000 Dec 23-30;321(7276):1591-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11124191">Pubmed</a></li>
	<li>Aukerman G, Knutson D, Miser WF: Management of the acute migraine headache. Am Fam Physician. 2002 Dec 1;66(11):2123-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12484694">Pubmed</a></li>
	<li>Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: <span class="caps">ISIS</span>-2. <span class="caps">ISIS</span>-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988 Aug 13;2(8607):349-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2899772">Pubmed</a></li>
	<li>Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS: Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. Ann Pharmacother. 2007 May;41(5):737-41. Epub 2007 Apr 24. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17456544">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00109" target="_blank">D00109 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C01405" target="_blank">C01405 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2244" target="_blank">2244 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505803" target="_blank">46505803 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.2157.html" target="_blank">2157 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=22360" target="_blank">22360 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=15365" target="_blank">15365 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL25" target="_blank">CHEMBL25 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000843" target="_blank">DAP000843 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA448497" target="_blank">PA448497 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=4139" target="_blank">4139 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4139" target="_blank">4139 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>HET</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/msd-srv/chempdb/cgi-bin/cgi.pl?FUNCTION=getByCode&amp;CODE=AIN" target="_blank">AIN <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2237900" target="_blank">2237900 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/asa.htm" target="_blank">http://www.rxlist.com/cgi/generic/asa.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/aspirin.html" target="_blank">http://www.drugs.com/aspirin.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/asp1033.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/asp1033.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Aspirin" target="_blank">Aspirin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>A01AD05<ul class="atc-drug-tree"><li><a href="/atc/A#A">A &#8212; ALIMENTARY TRACT AND METABOLISM</a></li><li><a href="/atc/A01#A01">A01 &#8212; STOMATOLOGICAL PREPARATIONS</a></li><li><a href="/atc/A01A#A01A">A01A &#8212; STOMATOLOGICAL PREPARATIONS</a></li><li><a href="/atc/A01AD#A01AD">A01AD &#8212; Other agents for local oral treatment</a></li></ul>B01AC06<ul class="atc-drug-tree"><li><a href="/atc/B#B">B &#8212; BLOOD AND BLOOD FORMING ORGANS</a></li><li><a href="/atc/B01#B01">B01 &#8212; ANTITHROMBOTIC AGENTS</a></li><li><a href="/atc/B01A#B01A">B01A &#8212; ANTITHROMBOTIC AGENTS</a></li><li><a href="/atc/B01AC#B01AC">B01AC &#8212; Platelet aggregation inhibitors excl. heparin</a></li></ul>N02BA01<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N02#N02">N02 &#8212; ANALGESICS</a></li><li><a href="/atc/N02B#N02B">N02B &#8212; OTHER ANALGESICS AND ANTIPYRETICS</a></li><li><a href="/atc/N02BA#N02BA">N02BA &#8212; Salicylic acid and derivatives</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:08.04.24</li>
<li>92:02.00*</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00945.pdf?1265922814">show</a>(889 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00945.pdf?1265922750">show</a>(18.9 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Acetylsalicylic acid increases the effect of the anticoagulant, acenocoumarol.</td></tr><tr><td><a href="/drugs/DB00819">Acetazolamide</a></td><td>Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, acetazolamide.</td></tr><tr><td><a href="/drugs/DB00414">Acetohexamide</a></td><td>Acetylsalicylic acid increases the effect of sulfonylurea, acetohexamide.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Acetylsalicylic acid increases effect of the anticoagulant, anisindione.</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>The corticosteroid, betamethasone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB00672">Chlorpropamide</a></td><td>Acetylsalicylic acid may increase the effect of the sulfonylurea, chlorpropamide.</td></tr><tr><td><a href="/drugs/DB01380">Cortisone acetate</a></td><td>The corticosteroid, cortisone acetate, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>The corticosteroid, dexamethasone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB01144">Diclofenamide</a></td><td>Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, dichlorphenamide.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Acetylsalicylic acid increases effect of the anticoagulant, dicumarol.</td></tr><tr><td><a href="/drugs/DB06210">Eltrombopag</a></td><td>Decreases metabolism, will increase effect/level of eltrombopag.</td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>The corticosteroid, fludrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01120">Gliclazide</a></td><td>Acetylsalicylic acid increases the effect of the sulfonylurea, gliclazide.</td></tr><tr><td><a href="/drugs/DB01067">Glipizide</a></td><td>Acetylsalicylic acid increases the effect of the sulfonylurea, glipizide.</td></tr><tr><td><a href="/drugs/DB01289">Glisoxepide</a></td><td>Acetylsalicylic acid increases the effect of the sulfonylurea, glisoxepide.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>Acetylsalicylic acid increases the effect of the sulfonylurea, glibenclamide.</td></tr><tr><td><a href="/drugs/DB01382">Glycodiazine</a></td><td>Acetylsalicylic acid increases the effect of sulfonylurea, glycodiazine.</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>Griseofulvin may decrease the efficacy of acetylsalicylic acid. </td></tr><tr><td><a href="/drugs/DB01109">Heparin</a></td><td>Increased risk of bleeding. </td></tr><tr><td><a href="/drugs/DB04865">Homoharringtonine</a></td><td>Avoid combination with acetylsalicylic acid due to the potential enhancement of homoharringtonine associated bleeding-related adverse effects. Specifically it is suggested to avoid this combination in patients with a platelet count of less than 50,000/uL. </td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended.</td></tr><tr><td><a href="/drugs/DB01009">Ketoprofen</a></td><td>Concomitant therapy of the NSAID, ketoprofen, and acetylsalicylic acid may result in additive adverse/toxic effects (e.g. GI bleeding). The NSAID may also limit the cardioprotective effect of acetylsalicylic acid. Occasional concomitant use may not cause clinically significant problems, but regular, frequent concomitant therapy is not recommended. </td></tr><tr><td><a href="/drugs/DB00465">Ketorolac</a></td><td>Acetylsalicylic acid may increase the adverse GI effects ketorolac.</td></tr><tr><td><a href="/drugs/DB00703">Methazolamide</a></td><td>Acetylsalicylic acid at high dose increases the effect of the carbonic anhydrase inhibitor, methazolamide.</td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>Acetylsalicylic acid increases the effect and toxicity of methotrexate.</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>The corticosteroid, methylprednisolone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB01384">Paramethasone</a></td><td>The corticosteroid, paramethasone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The corticosteroid, prednisolone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The corticosteroid, prednisone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB01032">Probenecid</a></td><td>Acetylsalicylic acid decreases the uricosuric effect of probenecid.</td></tr><tr><td><a href="/drugs/DB00605">Sulindac</a></td><td>Risk of additive toxicity (e.g. bleed risk). Acetylsalicylic acid may decrease the serum concentration of sulindac. Sulindac may counteract the cardioprotective effects of acetylsalicylic acid. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if the interacting agent is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00966">Telmisartan</a></td><td>Concomitant use of Telmisartan and Acetylsalicylic acid may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. </td></tr><tr><td><a href="/drugs/DB01600">Tiaprofenic acid</a></td><td>Increased risk of gastrointestinal bleeding. </td></tr><tr><td><a href="/drugs/DB00208">Ticlopidine</a></td><td>Increased effect of ticlopidine</td></tr><tr><td><a href="/drugs/DB00839">Tolazamide</a></td><td>Acetylsalicylic acid increases the effect of the sulfonylurea, tolazamide.</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Acetylsalicylic acid increases the effect of the sulfonylurea, tolbutamide.</td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>Additive adverse effects increase the risk of gastrointestinal bleeding. Possible decrease in the cardioprotective effect of acetylsalicylic acid. Monitor for increased bleeding risk during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Acetylsalicylic acid may reduce the efficacy of Trandolapril. Monitor for changes in Trandolapril efficacy if Acetylsalicylic acid is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Acetylsalicylic acid. Monitor for increased bleeding during concomitant thearpy. </td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>The corticosteroid, triamcinolone, may decrease the effect of the salicylate, acetylsalicylic acid.</td></tr><tr><td><a href="/drugs/DB00313">Valproic Acid</a></td><td>Acetylsalicylic acid increases the effect of valproic acid.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>The antiplatelet effects of acetylsalicylic acid may increase the bleed risk associated with warfarin.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol, alcohol appears to cause a 50 to 100% increases in ASA serum levels.</li>
<li>Take with a full glass of water.</li>
<li>Take with food to reduce gastric irritation.</li></ul></td></tr></tbody></table>